Simvastatin vs atorvastatin.
Both inhibit the same enzyme, so this comparison is entirely about potency and pharmacokinetics. Those two properties decide when the tablet is taken and which other drugs force a dose reduction, which is most of what prescribing a statin actually involves.
Atorvastatin is higher intensity and has a long half-life, so it can be taken at any time of day. Simvastatin is shorter acting and must be taken in the evening when cholesterol synthesis peaks, and it carries far tighter dose restrictions when combined with CYP3A4 inhibitors.
Simvastatin vs Atorvastatin at a glance
| Property | Simvastatin | Atorvastatin |
|---|---|---|
| Intensity | Moderate | High at usual doses |
| Half-life | Short | Long, around 14 hours with active metabolites |
| Timing | Evening | Any time of day |
| CYP3A4 substrate | Yes, heavily | Yes, less restrictively |
| Dose caps with interacting drugs | Strict, some combinations contraindicated | Present but less restrictive |
| Renal impairment | Caution at high dose | Generally usable |
Why only one needs evening dosing
Hepatic cholesterol synthesis runs highest overnight, so a short-acting inhibitor should be present then. Simvastatin has a short half-life and is therefore taken in the evening. Atorvastatin lasts long enough that the timing makes no practical difference, which is a small but genuine adherence advantage.
Why the CYP3A4 interaction bites harder for simvastatin
Statin myopathy risk rises with plasma concentration, and simvastatin undergoes extensive CYP3A4 metabolism with low oral bioavailability, so inhibiting that enzyme raises its levels sharply. This is why specific dose caps exist for simvastatin with drugs such as amlodipine and diltiazem, and why some combinations are avoided altogether. Atorvastatin is also a CYP3A4 substrate but is less dramatically affected.
Why intensity matters more than the molecule
Guidelines increasingly specify statin intensity rather than a named drug, because the outcome benefit tracks the percentage reduction in LDL rather than which molecule achieved it. A question asking which statin to use after a myocardial infarction is usually asking for high intensity therapy, and atorvastatin or rosuvastatin are the usual answers.
Which one would the question pick?
Exams rarely ask what a drug does. They describe a patient and ask which of the two you would choose, so the scenarios below matter more than either drug monograph.
| Scenario | Pick | Why |
|---|---|---|
| Secondary prevention after infarction | Atorvastatin | High intensity therapy is indicated. |
| Patient taking a CYP3A4 inhibitor | Atorvastatin or a non-CYP3A4 statin | Simvastatin carries stricter dose caps and some contraindications. |
| Adherence limited by dose timing | Atorvastatin | Long half-life removes the evening dosing requirement. |
Traps that catch people on this pair
Applying the grapefruit warning to every statin
It matters for simvastatin and atorvastatin, which are CYP3A4 substrates, and barely at all for rosuvastatin or pravastatin.
Telling every statin patient to dose at night
Only the short-acting agents need evening dosing. For atorvastatin and rosuvastatin, timing is irrelevant.
Common questions
What is the difference between simvastatin and atorvastatin?
Atorvastatin is higher intensity and has a long half-life, so it can be taken at any time of day. Simvastatin is shorter acting and must be taken in the evening when cholesterol synthesis peaks, and it carries far tighter dose restrictions when combined with CYP3A4 inhibitors.
Is atorvastatin stronger than simvastatin?
Yes at usual doses. Atorvastatin is a high intensity statin and simvastatin is moderate intensity, meaning atorvastatin produces a larger percentage reduction in LDL cholesterol.
Why is simvastatin taken at night?
Hepatic cholesterol synthesis peaks overnight and simvastatin has a short half-life, so evening dosing puts the drug where it is needed. Atorvastatin lasts long enough that timing does not matter.
Which statin has more drug interactions?
Simvastatin. It is heavily metabolised by CYP3A4 with low bioavailability, so inhibitors raise its levels sharply, which is why strict dose caps apply with drugs such as amlodipine and diltiazem.
Go deeper on the mechanism
A comparison only sticks once the shared mechanism underneath it does, because what separates two drugs is always a variation on something they have in common.
- Statins — the class both drugs belong to
- Cardiovascular pharmacology questions — test the distinction under time
- Statins, grapefruit and CYP3A4
Other comparisons
Heparin vs Warfarin · Warfarin vs DOACs · Unfractionated heparin vs Enoxaparin · Propranolol vs Atenolol · Metoprolol vs Atenolol · Amlodipine vs Nifedipine · Furosemide vs Bendroflumethiazide · Spironolactone vs Eplerenone · All comparisons
Study aid only. This page is written for learning and examination practice. It is not medical advice, not clinical decision support, and must never be used to make a decision about a real patient. Always verify against your local formulary, the product literature and a qualified pharmacist. See our medical disclaimer.
Two drugs, one property apart.
PharmBit teaches the shared mechanism first, then the single difference that splits the pair. Free download, no credit card.
Free to download. 7-day Pro trial. Cancel anytime.